PH Denaturation of dsRNA for mRNA Purification

Why It Matters

The technique dramatically cuts immunogenic dsRNA, improving vaccine efficacy and manufacturing yields, a critical advantage as mRNA therapeutics expand globally.

Key Takeaways

• pH < 3.5 denatures dsRNA within seconds
• mRNA recovery exceeds 90% while dsRNA drops below 0.1%
• Method compatible with oligo‑dT affinity chromatography
• Acidic treatment reversible; salts can re‑form dsRNA
• Scalable, non‑hazardous, avoids organic solvents

Pulse Analysis

The presence of double‑stranded RNA is a long‑standing bottleneck in mRNA biomanufacturing, triggering innate immune responses that can blunt vaccine potency and therapeutic safety. Traditional downstream strategies—cellulose filtration for dsRNA removal or reverse‑phase chromatography—suffer from low product recovery or reliance on harsh organic solvents, respectively. As the mRNA market accelerates, manufacturers demand a solution that preserves yield, maintains product integrity, and fits within existing purification trains.

The newly reported low‑pH denaturation protocol exploits the pH‑sensitivity of hydrogen bonds between adenine‑cytosine pairs, causing dsRNA to unravel in under five seconds at pH 3.5 or lower. Empirical data across 1‑10 kb constructs show dsRNA immunoblot signals vanish, while mRNA integrity remains intact, delivering >90% recovery and a >5‑fold increase in functional expression in A549 cells. Crucially, the method dovetails with oligo‑dT affinity chromatography, a clinically validated platform, by performing an inline acidic pre‑treatment that prevents dsRNA re‑formation when salts are later introduced for binding.

From a commercial perspective, the process is inexpensive, scalable, and free of hazardous reagents, aligning with GMP constraints and reducing capital expenditures on specialized chromatography skids. Its reversibility in the presence of kosmotropic salts underscores the need for careful process integration, but also offers flexibility for downstream formulation steps. As mRNA therapeutics move toward gram‑scale clinical batches, this pH‑based dsRNA mitigation could become a standard pre‑purification step, delivering higher yields, lower immunogenicity, and faster time‑to‑market for next‑generation vaccines and gene‑editing therapies.